Idenix Gets a Big Buy Rec

Deutsche Bank just gave Idenix (Nasdaq: IDIX  ) a big buy recommendation, projecting a stock price of $7 per share, which is more than 55% higher than what the stock closed at yesterday, and the stock climbed 15% as a result. Its drug IDX-184 is still in development and on clinical hold because of its similarities with a drug from Bristol-Myers Squibb (NYSE: BMY  ) that had catastrophic results. But it's aimed at the hottest area in health care right now -- the treatment of hepatitis-C -- and Deutsche Bank thinks it is significantly different from Bristol's drug. Many wonder, however, if it isn't too late for a small company to enter this space, as drug cocktails demonstrating miraculous cure rates are already further along in development from both Abbott Labs (NYSE: ABT  ) and Gilead (Nasdaq: GILD  ) .

See more in the following video.

With the impending spinoff of its branded-drug business, Abbott Labs is losing a massive blockbuster drug in Humira. It's a confusing event to understand, with many investors left wondering what to do with these two stocks once they're separated. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2131441, ~/Articles/ArticleHandler.aspx, 9/3/2014 3:19:34 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement